Richard J. Honeywell

20072020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Article
2020

Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function

Van Der Steen, N., Keller, K., Dekker, H., Porcelli, L., Honeywell, R. J., Van Meerloo, J., Musters, R. J. P., Kathmann, I., Frampton, A. E., Liu, D. S. K., Ruijtenbeek, R., Rolfo, C., Pauwels, P., Giovannetti, E. & Peters, G. J., 1 Jan 2020, In : Journal of Cellular Physiology.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access
2019

Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell Lines

Noordhuis, P., Laan, A. C., van de Born, K., Honeywell, R. J. & Peters, G. J., 2019, In : International Journal of Molecular Sciences. 20, 15

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment

Balboni, B., el Hassouni, B., Honeywell, R. J., Sarkisjan, D., Giovannetti, E., Poore, J., Heaton, C., Peterson, C., Benaim, E., Lee, Y. B., Kim, D. J. & Peters, G. J., 3 Apr 2019, In : Expert Opinion on Investigational Drugs. 28, 4, p. 311-322 12 p.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access
2018

Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study

Tibaldi, C., Camerini, A., Tiseo, M., Mazzoni, F., Barbieri, F., Vittimberga, I., Brighenti, M., Boni, L., Baldini, E., Gilli, A., Honeywell, R., Chartoire, M., Peters, G. J., Giovannetti, E. & Italian Oncological Group of Clinical Research (GOIRC), 27 Nov 2018, In : British Journal of Cancer. 119, 11, p. 1326-1331 6 p.

Research output: Contribution to journalArticleAcademicpeer-review

DNA methyltransferases expression in normal tissues and various human cancer cell lines, xenografts and tumors.

Honeywell, R. J., Sarkisjan, D., Kristensen, M. H., de Klerk, D. J. & Peters, G. J., 2 Dec 2018, In : Nucleosides, Nucleotides and Nucleic Acids. 37, 12, p. 696-708 13 p.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab

Walraven, M., Homs, M. Y. V., van der Veldt, A. A. M., Dekker, H., Koldenhof, J., Honeywell, R., Barendrecht, A., Sebastian, S. A. E., Parr, N., Koekman, A. C., Voest, E. E., Roest, M., Korporaal, S. J. A. & Verheul, H. M. W., 2018, In : Angiogenesis. 21, 2, p. 325-334

Research output: Contribution to journalArticleAcademicpeer-review

Open Access
Open Access

Subcellular localization of several structurally different tyrosine kinase inhibitors

Honeywell, R. J., Hitzerd, S. M., Kathmann, G. A. M. & Peters, G. J., 2018, In : ADMET & DMPK. 6, 3, p. 258-266

Research output: Contribution to journalArticleAcademicpeer-review

Open Access
2017

Rapid homogeneous immunoassay to quantify gemcitabine in plasma for therapeutic drug monitoring

Kozo, D., Ross, M. W., Jarrah, J., Barrett, M., Harney, R. L., Courtney, J. B., Baburina, I., Holleran, J. L., Beumer, J. H., Peters, G. J., Honeywell, R. J. & Salamone, S. J., 1 Jun 2017, In : Therapeutic Drug Monitoring. 39, 3, p. 235-242 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

2016

Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice

Timmers, L., Boons, C. C. L. M., Mangnus, D., Van de Ven, P. M., Van den Berg, P. H., Beeker, A., Swart, E. L., Honeywell, R. J., Peters, G. J., Boven, E. & Hugtenburg, J. G., 21 Sep 2016, In : Frontiers in Pharmacology. 7

Research output: Contribution to journalArticleAcademicpeer-review

Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR

Verbrugge, C., Al, M., Assaraf, Y. G., Kammerer, S., Chandrupatla, D. M. S. H., Honeywell, R. J., Musters, R. P. J., Giovannetti, E., O'Toole, T., Scheffer, G. L., Krige, D., de Gruijl, T. D., Niessen, J., Lems, W. F., Kramer, P. A., Scheper, R. J., Cloos, J., Ossenkoppele, G. J., Peters, G. J. & Jansen, G., 2 Feb 2016, In : Oncotarget. 7, 5, p. 5240-5257

Research output: Contribution to journalArticleAcademicpeer-review

Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib

Muller, I. B., De Langen, A. J., Honeywell, R. J., Giovannetti, E. & Peters, G. J., 1 Feb 2016, In : Expert Review of Anticancer Therapy. 16, 2, p. 147-157

Research output: Contribution to journalArticleAcademicpeer-review

Tissue distribution of Crizotinib and Gemcitabine combination in a patient-derived orthotopic mouse model of pancreatic cancer

Honeywell, RJ., Avan, A., Giovannetti, E. & Peters, GJ., 2016, In : ADMET & DMPK. 4, p. 327-334

Research output: Contribution to journalArticleAcademicpeer-review

Transport of six tyrosine kinase inhibitors: active or passive?

Peters, GJ., Honeywell, RJ., Hilzerd, S. & Kathman, I., 2016, In : ADMET & DMPK. 4, p. 23-34

Research output: Contribution to journalArticleAcademicpeer-review

2015

Adaptation of a human gut epithelial model in relation to the assessment of clinical pharmacokinetic parameters for selected tyrosine kinase inhibitors

Honeywell, R. J., Fatmawati, C., Buddha, M., Hitzerd, S., Kathmann, I. & Peters, G. J., 2015, In : ADMET & DMPK. 3, 1, p. 51-67

Research output: Contribution to journalArticleAcademicpeer-review

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib

Gotink, K. J., Rovithi, M. N., de Haas, R. R., Honeywell, R. J., Dekker, H., Poel, D., Azijli, K., Peters, G. J., Broxterman, H. J. & Verheul, H. M. W., 2015, In : Cellular Oncology. 38, 2, p. 119-129

Research output: Contribution to journalArticleAcademicpeer-review

Drug transport and metabolism of novel anticancer drugs

Peters, G. J. & Honeywell, R. J., 2015, In : Expert Opinion on Drug Metabolism and Toxicology. 11, 5, p. 661-663

Research output: Contribution to journalArticleAcademicpeer-review

Inhibition of thymidylate synthase by 2 ',2 '-difluoro-2 '-deoxycytidine (Gemcitabine) and its metabolite 2 ',2 '-difluoro-2 '-deoxyuridine

Honeywell, R. J., van Haperen, V. W. T. R., Veerman, G., Smid, K. & Peters, G. J., 2015, In : International Journal of Biochemistry & Cell Biology. 60, p. 73-81

Research output: Contribution to journalArticleAcademicpeer-review

Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction

Kleibeuker, E. A., ten Hooven, M. A., Castricum, K. C., Honeywell, R. J., Griffioen, A. W., Verheul, H. M., Slotman, B. J. & Thijssen, V. L. J. L., 2015, In : Cancer Medicine. 4, 7, p. 1003-1015

Research output: Contribution to journalArticleAcademicpeer-review

Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters

Da Silva, C. G., Honeywell, R. J., Dekker, H. & Peters, G. J., 2015, In : Expert Opinion on Drug Metabolism and Toxicology. 11, 5, p. 703-717

Research output: Contribution to journalArticleAcademicpeer-review

2014

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature

Gotink, K. J., Broxterman, H. J., Honeywell, R. J., Dekker, H., de Haas, R. R., Miles, K. M., Adelaiye, R., Griffioen, A. W., Peters, G. J., Pili, R. & Verheul, H. M. W., 2014, In : Oncoscience. 1, 12, p. 844-853

Research output: Contribution to journalArticleAcademicpeer-review

Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine

Adema, A. D., Floor, K., Smid, K., Honeywell, R. J., Scheffer, G. L., Jansen, G. & Peters, G. J., 2014, In : SpringerPlus. 3, 732.

Research output: Contribution to journalArticleAcademicpeer-review

Selection of the Best Blood Compartment to Measure Cytidine Deaminase Activity to Stratify for Optimal Gemcitabine Or Cytarabine Treatment

Peters, G. J., Honeywell, R. J., Maulandi, M., Giovannetti, E., Losekoot, N., Etienne-Grimaldi, M. C., Milano, G., Serdjebi, C. & Ciccolini, J., 2014, In : Nucleosides, Nucleotides and Nucleic Acids. 33, 4-6, p. 403-412

Research output: Contribution to journalArticleAcademicpeer-review

Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia

Maftouh, M., Avan, A., Sciarrillo, R., Granchi, C., Leon, L. G., Rani, R., Funel, N., Smid, K., Honeywell, R. J., Boggi, U., Minutolo, F., Peters, G. J. & Giovannetti, E., 2014, In : British Journal of Cancer. 110, 1, p. 172-182

Research output: Contribution to journalArticleAcademicpeer-review

2013

Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met-driven Pancreatic Carcinoma

Avan, A., Caretti, V., Funel, N., Galvani, E., Maftouh, M., Honeywell, R. J., Lagerweij, T., van Tellingen, O., Campani, D., Fuchs, D., Verheul, H. M., Schuurhuis, G. J., Boggi, U., Peters, G. J., Wurdinger, T. & Giovannetti, E., 2013, In : Cancer Research. 73, 22, p. 6745-6756

Research output: Contribution to journalArticleAcademicpeer-review

DNA-Bound Platinum Is the Major Determinant of Cisplatin Sensitivity in Head and Neck Squamous Carcinoma Cells

de Kemp, S. R., Dalm, S. U., Wijnolts, F. M. J., van den Brink, A., Honeywell, R. J., Peters, G. J., Braakhuis, B. J. M. & Brakenhoff, R. H., 2013, In : PLoS ONE. 8, 4, e61555.

Research output: Contribution to journalArticleAcademicpeer-review

Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360)

Peters, G. J., Smid, K., Vecchi, L., Kathmann, I., Sarkisjan, D., Honeywell, R. J., Losekoot, N., Ohne, O., Orbach, A., Blaugrund, E., Jeong, L. S., Lee, Y. B., Ahn, C. H. & Kim, D. J., 2013, In : Investigational New Drugs. 31, 6, p. 1444-1457

Research output: Contribution to journalArticleAcademicpeer-review

Pemetrexed Induced Thymidylate Synthase Inhibition in Non-Small Cell Lung Cancer Patients: A Pilot Study with 3 '-Deoxy-3 '-[F-18]fluorothymidine Positron Emission Tomography

Frings, V., van der Veldt, A. A. M., Boellaard, R., Herder, G. J. M., Giovannetti, E., Honeywell, R. J., Peters, G. J., Thunnissen, E., Hoekstra, O. S. & Smit, E. F., 2013, In : PLoS ONE. 8, 5, e63705.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access
File
68 Downloads (Pure)

Successful Treatment of Renal Cell Carcinoma With Sorafenib After Effective but Hepatotoxic Sunitinib Exposure

Westgeest, H. M., van Erp, N. P., Honeywell, R. J., Hoekstra, R., Peters, G. J. & Verheul, H. M. W., 2013, In : Journal of Clinical Oncology. 31, 6, p. E83-E86

Research output: Contribution to journalArticleAcademicpeer-review

2012

Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients

Tibaldi, C., Giovannetti, E., Tiseo, M., Leon, L. G., D'Incecco, A., Losekoot, N., Bartolotti, M., Honeywell, R. J., Cappuzzo, F., Ardizzoni, A. & Peters, G. J., 2012, In : Annals of Oncology. 23, 3, p. 670-677

Research output: Contribution to journalArticleAcademicpeer-review

Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126

Adema, A. D., Smid, K., Losekoot, N., Honeywell, R. J., Verheul, H. M. W., Myhren, F., Sandvold, M. & Peters, G. J., 2012, In : Investigational New Drugs. 30, 5, p. 1908-1916

Research output: Contribution to journalArticleAcademicpeer-review

Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells

Avan, A., Crea, F., Paolicchi, E., Funel, N., Galvani, E., Marquez, V. E., Honeywell, R. J., Danesi, R., Peters, G. J. & Giovannetti, E., 2012, In : Molecular Cancer Therapeutics. 11, 8, p. 1735-1746

Research output: Contribution to journalArticleAcademicpeer-review

2011

Cellular pharmacology of multi- and duplex drugsconsisting of ethynylcytidine and 5-fluoro-2 '-deoxyuridine

Bijnsdorp, I. V., Schwendener, R. A., Schott, H., Fichtner, I., Smid, K., Laan, A. C., Schott, S., Losekoot, N., Honeywell, R. J. & Peters, G. J., 2011, In : Investigational New Drugs. 29, 2, p. 248-257

Research output: Contribution to journalArticleAcademicpeer-review

Open Access
File
64 Downloads (Pure)

Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance

Gotink, K. J., Broxterman, H. J., Labots, M., de Haas, R. R., Dekker, H., Honeywell, R. J., Rudek, M. A., Beerepoot, L. V., Musters, R. J. P., Jansen, G., Griffioen, A. W., Assaraf, Y. G., Pili, R., Peters, G. J. & Verheul, H. M. W., 2011, In : Clinical Cancer Research. 17, 23, p. 7337-7346

Research output: Contribution to journalArticleAcademicpeer-review

2010

A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer

Lind, J. S. W., Dingemans, A. M. C., Groen, H. J. M., Thunnissen, F. B. J. M., Bekers, O., Heideman, D. A. M., Honeywell, R. J., Giovannetti, E., Peters, G. J., Postmus, P. E., van Suylen, R. J. & Smit, E. F., 2010, In : Clinical Cancer Research. 16, 11, p. 3078-3087

Research output: Contribution to journalArticleAcademicpeer-review

Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)

Giovannetti, E., Honeywell, R. J., Hanauske, A. R., Tekle, C., Kuenen, B., Sigmond, J., Giaccone, G. & Peters, G. J., 2010, In : Current Drug Targets. 11, 1, p. 12-28

Research output: Contribution to journalArticleAcademicpeer-review

Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry

Honeywell, R. J., Yarzadah, K., Giovannetti, E., Losekoot, N., Smit, E. F., Walraven, M., Lind, J. S. W., Tibaldi, C., Verheul, H. M. W. & Peters, G. J., 2010, In : Journal of Chromatography B. 878, 15-16, p. 1059-1068

Research output: Contribution to journalArticleAcademicpeer-review

Trifluorothymidine Resistance Is Associated with Decreased Thymidine Kinase and Equilibrative Nucleoside Transporter Expression or Increased Secretory Phospholipase A2

Temmink, O. H., Bijnsdorp, I. V., Prins, H. J., Losekoot, N., Adema, A. D., Smid, K., Honeywell, R. J., Ylstra, B., Eijk, P. P., Fukushima, M. & Peters, G. J., 2010, In : Molecular Cancer Therapeutics. 9, 4, p. 1047-1057

Research output: Contribution to journalArticleAcademicpeer-review

2009

A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion

van Riel, J. M. G. H., Peters, G. J., Mammatas, L. H., Honeywell, R. J., Laan, A. C., Ruijter, R., van den Berg, F. G., Giaccone, G. & van Groeningen, C. J., 2009, In : European Journal of Cancer. 45, 14, p. 2519-2527

Research output: Contribution to journalArticleAcademicpeer-review

Cell Cycle Effects and Increased Adduct Formation by Temozolomide Enhance the Effect of Cytotoxic and Targeted Agents in Lung Cancer Cell Lines

Adema, A. D., van der Born, K., Honeywell, R. J. & Peters, G. J., 2009, In : Journal of chemotherapy. 21, 3, p. 338-346

Research output: Contribution to journalArticleAcademicpeer-review